Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription


3 Antiviral Res
1 Arch Virol
1 BMC Pediatr
3 J Gen Virol
2 Minerva Pediatr (Torino)
1 N Engl J Med
2 PLoS Comput Biol
27 PLoS One
3 Proc Natl Acad Sci U S A
10 Vaccine
1 Virology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Antiviral Res

  1. ANDREEV K, Jones JC, Seiler P, Kandeil A, et al
    Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors.
    Antiviral Res. 2024 Jul 8:105959. doi: 10.1016/j.antiviral.2024.105959.
    PubMed         Abstract available

  2. XU Y, Sun F, Chuai Z, Wang J, et al
    Cold-adapted influenza vaccine carrying three repeats of a respiratory syncytial virus (RSV) fusion glycoprotein epitope site protects BALB/c mice and cotton rats against RSV infection.
    Antiviral Res. 2024 Jul 8:105960. doi: 10.1016/j.antiviral.2024.105960.
    PubMed         Abstract available

  3. CHON I, Wagatsuma K, Saito R, Tang JW, et al
    Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022-2023 influenza season in Japan.
    Antiviral Res. 2024 Jul 3:105956. doi: 10.1016/j.antiviral.2024.105956.
    PubMed         Abstract available

    Arch Virol

  4. FANG F, Wang B, Lu X, Wang L, et al
    miR-126a-5p inhibits H1N1-induced inflammation and matrix protease secretion in lung fibroblasts by targeting ADAMTS-4.
    Arch Virol. 2024;169:164.
    PubMed         Abstract available

    BMC Pediatr

  5. MALLA L, Ohuma EO, Shabani J, Ngwala S, et al
    COVID-19 pandemic effects on neonatal inpatient admissions and mortality: interrupted time series analysis of facilities implementing NEST360 in Kenya, Malawi, Nigeria, and Tanzania.
    BMC Pediatr. 2024;23.
    PubMed         Abstract available


    Looking for a helping hand.
    BMJ. 2024;386:q1006.

  7. Seven days in medicine: 3-9 July 2024.
    BMJ. 2024;386:q1510.

    Mpox: South Africa reports 20 new cases and three deaths.
    BMJ. 2024;386:q1529.

    Industrial action: New health secretary opens talks with junior doctors.
    BMJ. 2024;386:q1514.

    UK general election: Nine doctors are elected as MPs.
    BMJ. 2024;386:q1494.

  11. MAHASE E
    Covid-19: Are we seeing a summer wave?
    BMJ. 2024;386:q1496.

    Conservative Party's legacy on the NHS.
    BMJ. 2024;386:q1491.
    PubMed         Abstract available

    J Gen Virol

  13. KING J, Pohlmann A, Bange A, Horn E, et al
    Red knots in Europe: a dead end host species or a new niche for highly pathogenic avian influenza?
    J Gen Virol. 2024;105.
    PubMed         Abstract available

  14. JAMES J, Thomas SS, Seekings AH, Mahmood S, et al
    Evaluating the epizootic and zoonotic threat of an H7N9 low-pathogenicity avian influenza virus (LPAIV) variant associated with enhanced pathogenicity in turkeys.
    J Gen Virol. 2024;105.
    PubMed         Abstract available

  15. HAVERTY R, McCormack J, Evans C, Purves K, et al
    SARS-CoV-2 infects neurons, astrocytes, choroid plexus epithelial cells and pericytes of the human central nervous system in vitro.
    J Gen Virol. 2024;105.
    PubMed         Abstract available


  16. HARRIS E
    Review Calls for Standardized Long COVID Definition.
    JAMA. 2024;332:97.

  17. ANGUS DC, Huang AJ, Lewis RJ, Abernethy AP, et al
    The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided.
    JAMA. 2024 Jun 3. doi: 10.1001/jama.2024.4088.
    PubMed         Abstract available

    Minerva Pediatr (Torino)

  18. FILLON A, Lambert C, Tardieu M, Genin P, et al
    Impact of the COVID-19 confinement on movement behaviors among French young children: the ONAPS national survey.
    Minerva Pediatr (Torino). 2024;76:478-486.
    PubMed         Abstract available

  19. ARETI S, Parrillo M, Baker L, Meszaros A, et al
    Multisystem inflammatory syndrome in children: an evolving understanding of a syndrome amid the inflammatory continuum.
    Minerva Pediatr (Torino). 2024;76:545-555.
    PubMed         Abstract available

    N Engl J Med

  20. ASSAD Z, Romain AS, Aupiais C, Shum M, et al
    Nirsevimab and Hospitalization for RSV Bronchiolitis.
    N Engl J Med. 2024;391:144-154.
    PubMed         Abstract available

    PLoS Comput Biol

  21. SALWIG S, Drefs J, Lucke J
    Zero-shot denoising of microscopy images recorded at high-resolution limits.
    PLoS Comput Biol. 2024;20:e1012192.
    PubMed         Abstract available

  22. HLADISH TJ, Pillai AN, Pearson CAB, Toh KB, et al
    Evaluating targeted COVID-19 vaccination strategies with agent-based modeling.
    PLoS Comput Biol. 2024;20:e1012128.
    PubMed         Abstract available

    PLoS One

  23. BARBIERI ES, Sosa-Holt C, Ibanez LI, Baztarrica J, et al
    Anti-hemagglutinin monomeric nanobody provides prophylactic immunity against H1 subtype influenza A viruses.
    PLoS One. 2024;19:e0301664.
    PubMed         Abstract available

  24. PRICE MA, Kuteesa M, Oladimeji M, Brumskine W, et al
    High STI burden among a cohort of adolescents aged 12-19 years in a youth-friendly clinic in South Africa.
    PLoS One. 2024;19:e0306771.
    PubMed         Abstract available

  25. NGUYEN TQ, Vlasenko D, Shetty AN, Reid CM, et al
    Laboratory-confirmed respiratory viral infection triggers for acute myocardial infarction and stroke: Systematic review protocol.
    PLoS One. 2024;19:e0302748.
    PubMed         Abstract available

  26. RABOL ANDERSEN L, Hindsberger B, Bastrup Israelsen S, Pedersen L, et al
    Higher levels of IL-1ra, IL-6, IL-8, MCP-1, MIP-3alpha, MIP-3beta, and fractalkine are associated with 90-day mortality in 132 non-immunomodulated hospitalized patients with COVID-19.
    PLoS One. 2024;19:e0306854.
    PubMed         Abstract available

  27. KOYAMA H, Sakai K, Fukaguchi K, Hadano H, et al
    A comparison study of temporal trends of SARS-CoV2 RNAemia and biomarkers to predict success and failure of high flow oxygen therapy among patients with moderate to severe COVID-19.
    PLoS One. 2024;19:e0305077.
    PubMed         Abstract available

  28. ELHADIDY HSMA, Politano G, Onorati R, Catozzi D, et al
    Impact of the COVID-19 pandemic on the complete rehabilitation journey of hip fracture patients in Italy: From surgical admission to rehabilitation facility discharge.
    PLoS One. 2024;19:e0305966.
    PubMed         Abstract available

  29. JAKUBOWSKI A, Egger D, Mulebeke R, Akankwasa P, et al
    Evaluation of a national program to distribute free face masks in Uganda: Evidence from Mbale District.
    PLoS One. 2024;19:e0305574.
    PubMed         Abstract available

  30. GRAY P, Eriksson T, Skoglund L, Lagheden C, et al
    Seroepidemiological assessment of the spread of SARS-CoV-2 among 25 and 28 year-old adult women in Finland between March 2020-June 2022.
    PLoS One. 2024;19:e0305285.
    PubMed         Abstract available

  31. CHEN KY, Stanford O, Wenzel JA, Joyner RL, et al
    Patient perspectives on cancer care during COVID-19: A qualitative study.
    PLoS One. 2024;19:e0306035.
    PubMed         Abstract available

  32. TALIE FENTA E, Bogale EK, Anagaw TF
    The role of social media on COVID-19 preventive behaviors worldwide, systematic review.
    PLoS One. 2024;19:e0306284.
    PubMed         Abstract available

  33. LAM CN, Lee R, Soto D, Ho A, et al
    The differential impacts of COVID-19 mortality on mental health by residential geographic regions: The Los Angeles Pandemic Surveillance Cohort Study.
    PLoS One. 2024;19:e0304779.
    PubMed         Abstract available

  34. YOUNES N, Chemaitelly H, Nizamuddin PB, Al-Hamad T, et al
    Prevalence of hepatitis A virus among migrant workers in Qatar: A national study.
    PLoS One. 2024;19:e0306753.
    PubMed         Abstract available

  35. MORISAWA F, Nishizaki Y, Nojiri S, Daida H, et al
    Association between physiotherapist sleep duration and working environment during the coronavirus disease 2019 pandemic in Japan: A secondary retrospective analysis study.
    PLoS One. 2024;19:e0306822.
    PubMed         Abstract available

  36. LAING R, Donnelly CA
    Evolution of an epidemic: Understanding the opioid epidemic in the United States and the impact of the COVID-19 pandemic on opioid-related mortality.
    PLoS One. 2024;19:e0306395.
    PubMed         Abstract available

  37. STRAIN JDR, Welch L, Sadler E
    Systematic review and narrative synthesis of the experiences of individuals with chronic pain participating in digital pain management interventions.
    PLoS One. 2024;19:e0306455.
    PubMed         Abstract available

  38. CURRAN JA, Lane J, McCulloch H, Keeping-Burke L, et al
    Uncovering the wider impact of COVID-19 measures on the lives of children with complex care needs and their families: A mixed-methods study protocol.
    PLoS One. 2024;19:e0305543.
    PubMed         Abstract available

  39. ISLAM N, Mohsin ASM, Choudhury SH, Shaer TP, et al
    COVID-19 and Pneumonia detection and web deployment from CT scan and X-ray images using deep learning.
    PLoS One. 2024;19:e0302413.
    PubMed         Abstract available

  40. OLANI KUTA A, Dida N
    Covid-19 vaccine hesitancy and its predictors among diabetic patients on follow-up at public hospitals in Nekemte Town, Western Ethiopia.
    PLoS One. 2024;19:e0305200.
    PubMed         Abstract available

  41. WIRTH B, Stucki M, Joerg R, Thommen C, et al
    Impact of the Covid-19 pandemic on inpatient health care in Switzerland 2020-2021-A descriptive retrospective study using admission data of all Swiss hospitals.
    PLoS One. 2024;19:e0306791.
    PubMed         Abstract available

  42. SSEGUYA W, Bahendeka S, MacLennan S, Mody N, et al
    Diabetes mellitus in sub-saharan Africa during the COVID-19 pandemic: A scoping review.
    PLoS One. 2024;19:e0305112.
    PubMed         Abstract available

  43. FUSTER-PARRA P, Huguet-Torres A, Castro-Sanchez E, Bennasar-Veny M, et al
    Identifying the interplay between protective measures and settings on the SARS-CoV-2 transmission using a Bayesian network.
    PLoS One. 2024;19:e0307041.
    PubMed         Abstract available

  44. ZHANG Q, Sun H, Lin Q, Lin K, et al
    Public network attention to hiking in China and its influencing factors.
    PLoS One. 2024;19:e0306726.
    PubMed         Abstract available

  45. LIANG H, Lee S, Sun J, Wong SC, et al
    Unraveling the causes of the Seoul Halloween crowd-crush disaster.
    PLoS One. 2024;19:e0306764.
    PubMed         Abstract available

  46. MAXWELL CJ, McArthur E, Hogan DB, Dampf H, et al
    Comparison of hospitalization events among residents of assisted living and nursing homes during COVID-19: Do settings respond differently during public health crises?
    PLoS One. 2024;19:e0306569.
    PubMed         Abstract available

  47. BONILLA-ESCOBAR FJ, Ghobrial AI, Gallagher DS, Eller A, et al
    Comprehensive insights into a decade-long journey: The evolution, impact, and human factors of an asynchronous telemedicine program for diabetic retinopathy screening in Pennsylvania, United States.
    PLoS One. 2024;19:e0305586.
    PubMed         Abstract available

  48. MANSOR E, Ahmad N, Mohd Zulkefli NA, Lim PY, et al
    Incidence and determinants of low birth weight in Peninsular Malaysia: A multicentre prospective cohort study.
    PLoS One. 2024;19:e0306387.
    PubMed         Abstract available

    Game location effect in game-related statistics and pre-shot combination differences between winners and losers during the basketball ACB COVID-19 season.
    PLoS One. 2024;19:e0303908.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  50. FERRER-ORTA C, Vazquez-Monteagudo S, Ferrero DS, Martinez-Gonzalez B, et al
    Point mutations at specific sites of the nsp12-nsp8 interface dramatically affect the RNA polymerization activity of SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2024;121:e2317977121.
    PubMed         Abstract available

    A balance between innovation and biosafety.
    Proc Natl Acad Sci U S A. 2024;121:e2410451121.

  52. HU Z, Lopez-Munoz AD, Kosik I, Li T, et al
    Recombinant OC43 SARS-CoV-2 spike replacement virus: An improved BSL-2 proxy virus for SARS-CoV-2 neutralization assays.
    Proc Natl Acad Sci U S A. 2024;121:e2310421121.
    PubMed         Abstract available


  53. JIMENEZ-SEPULVEDA N, Gras-Valenti P, Chico-Sanchez P, Castro-Garcia JM, et al
    Effectiveness of mRNA booster doses in preventing infections and hospitalizations due to SARS-CoV-2 and its dominant variant over time in Valencian healthcare workers, Spain.
    Vaccine. 2024;42:4011-4021.
    PubMed         Abstract available

  54. ANN COSTA CLEMENS S, Weckx L, Milan EP, Smolenov I, et al
    Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice.
    Vaccine. 2024 May 17:S0264-410X(24)00555-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  55. KARIMI-SHAHRBABAK E, Di Chiara C, Farrar DS, Abu Fadaleh SM, et al
    COVID-19 vaccine acceptance and uptake among caregivers of children aged 5-11?years in Ontario, Canada: A cross-sectional survey.
    Vaccine. 2024 May 20:S0264-410X(24)00553-X. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  56. ZHOU H, Zhao W, Ma R, Zheng Y, et al
    Mixed methods examination of risk perception on vaccination intentions: The perspective of doctor-patient communication.
    Vaccine. 2024 May 22:S0264-410X(24)00565-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  57. LANIECE DELAUNAY C, Melo A, Maurel M, Mazagatos C, et al
    Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023-January 2024.
    Vaccine. 2024 Jun 4:S0264-410X(24)00644-3. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  58. LE GARS M, Sadoff J, Cardenas V, Heerwegh D, et al
    Safety, reactogenicity, and immunogenicity of Ad26.COV2.S as homologous or heterologous COVID-19 booster vaccination: Results of a randomized, double-blind, phase 2 trial.
    Vaccine. 2024 Jun 24:S0264-410X(24)00401-8. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  59. NOWALK MP, Smith KJ, Raviotta JM, Wateska A, et al
    Cost-effectiveness of recombinant influenza vaccine compared with standard dose influenza vaccine in adults 18-64 years of age.
    Vaccine. 2024 Jul 5:S0264-410X(24)00748-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  60. BANG JY, Kim YJ, Seo YJ, Hong SH, et al
    Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.
    Vaccine. 2024 Jul 8:S0264-410X(24)00757-6. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  61. MUANGNOICHAROEN S, Wiangcharoen R, Lawpoolsri S, Nanthapisal S, et al
    Heterologous Ad26.COV2.S booster after primary BBIBP-CorV vaccination against SARS-CoV-2 infection: 1-year follow-up of a phase 1/2 open-label trial.
    Vaccine. 2024 May 13:S0264-410X(24)00556-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available

  62. LEE KY, Song KH, Lee KH, Baek JY, et al
    Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
    Vaccine. 2024 May 9:S0264-410X(24)00539-5. doi: 10.1016/j.vaccine.2024.
    PubMed         Abstract available


  63. LIU J, Ren T, Wang X, Wang H, et al
    The emergence, isolation, and phylogenetic analysis of a closely related human strain of parainfluenza virus 5 from a case of porcine reproductive and respiratory syndrome in China.
    Virology. 2024;597:110157.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.